Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 fatty acids and low-dose aspirin

Journal of Periodontology

Volumn 81, Issue 11, 2010, Pages 1635-1643

  El Sharkawy, Hesham ^a   Aboelsaad, Nayer ^a   Eliwa, Mohamed ^a   Darweesh, Mahmoud ^a   Alshahat, Mohammad ^a   Kantarci, Alpdogan ^b   Hasturk, Hatice ^b   Van Dyke, Thomas E ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Dietary supplements; Fatty acids; Matrix metalloproteinase 8; Periodontal diseases; RANK ligand

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; MMP8 PROTEIN, HUMAN; NEUTROPHIL COLLAGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

ADULT; AGED; ARTICLE; CHEMISTRY; CHRONIC PERIODONTITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIODONTAL DISEASE; PERIODONTAL POCKET; PERIODONTICS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; SALIVA; TOOTH PLAQUE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHRONIC PERIODONTITIS; COMBINED MODALITY THERAPY; DENTAL PLAQUE INDEX; DENTAL SCALING; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; FOLLOW-UP STUDIES; GINGIVAL HEMORRHAGE; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL INDEX; PERIODONTAL POCKET; PLACEBOS; RANK LIGAND; ROOT PLANING; SALIVA; TREATMENT OUTCOME;

EID: 78249278793     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.090628     Document Type: Article

References (64)

1. Kantarci A, Van Dyke TE. Lipoxin signaling in neutrophils and their role in periodontal disease. Prostaglandins Leukot Essent Fatty Acids 2005;73:289-299.
2. Lamster IB, Smith QT, Celenti RS, Singer RE, Grbic JT. Development of a risk profile for periodontal disease: Microbial and host response factors. J Periodontol 1994;65(Suppl. 5):511-520.
3. Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res 1991;26:230-242.
4. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
5. Van Dyke TE, Serhan CN. Resolution of inflammation: A new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90.
6. Bhatavadekar NB, Williams RC. New directions in host modulation for the management of periodontal disease. J Clin Periodontol 2009;36:124-126.
7. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol 2005;32(Suppl. 6):108-129.
8. Williams RC. Host modulation for the treatment of periodontal disease. Compend Contin Educ Dent 2008;29:160-162, 164, 166-168 passim.
9. Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 2002;73:762-769.
10. Ciancio SG. Systemic medications: Clinical significance in periodontics. J Clin Periodontol 2002;29(Suppl. 2):17-21.
11. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004;31:697-707.
12. Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 2008;53:354-357, quiz 366.
13. Barragan-Adjemian C, Lausten L, Ang DB, Johnson M, Katz J, Bonewald LF. Bisphosphonate-related osteonecrosis of the jaw: Model and diagnosis with cone beam computerized tomography. Cells Tissues Organs 2009;189:284-288.
14. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361.
15. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83(Suppl. 6):1505S-1519S.
16. Serhan CN, Hong S, Gronert K, et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037.
17. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: An overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 2004;73:155-172.
18. Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: A new paradigm for inflammatory resolution. FASEB J 2007;21:3162-3170.
19. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278:14677-14687.
20. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005;102:7671-7676.
21. Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005;201:713-722.
22. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003;278:43807-43817.
23. Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179:7021-7029.
24. Serhan CN. Novel chemical mediators in the resolution of inflammation: Resolvins and protectins. Anesthesiol Clin 2006;24:341-364.
25. Raffaelli L, Serini S, Piccioni E, et al. N-3 polyunsaturated fatty acid effect in periodontal disease: State of art and possible mechanisms involved. Int J Immunopathol Pharmacol 2008;21:261-266.
26. Vardar-Sengul S, Buduneli E, Turkoglu O, et al. The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. J Periodontol 2008;79:1934-1941.
27. Chen LY, Lawson DL, Mehta JL. Reduction in human neutrophil superoxide anion generation by n-3 polyunsaturated fatty acids: Role of cyclooxygenase products and endothelium-derived relaxing factor. Thromb Res 1994;76:317-322.
28. Kesavalu L, Vasudevan B, Raghu B, et al. Omega-3 fatty acid effect on alveolar bone loss in rats. J Dent Res 2006;85:648-652.
29. Kesavalu L, Bakthavatchalu V, Rahman MM, et al. Omega-3 fatty acid regulates inflammatory cytokine/mediator messenger RNA expression in Porphyromonas gingivalis-induced experimental periodontal disease. Oral Microbiol Immunol 2007;22:232-239.
30. Vardar S, Buduneli E, Baylas H, Berdeli AH, Buduneli N, Atilla G. Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2005;76:99-106.
31. Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 2005;338:149-157.
32. Hasturk H, Kantarci A, Ohira T, et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 2006;20:401-403.
33. Rai B, Kharb S, Jain R, Anand SC. Biomarkers of periodontitis in oral fluids. J Oral Sci 2008;50:53-56.
34. Miller CS, King CP Jr., Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: A cross-sectional study. J Am Dent Assoc 2006;137:322-329.
35. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol 2008;79:1913-1919.
36. Buduneli N, Biyikoǧlu B, Sherrabeh S, Lappin DF. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients. J Clin Periodontol 2008;35:846-852.
37. Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol 1970;41:41-43.
38. Gordon JM, Lamster IB, Seiger MC. Efficacy of Listerine antiseptic in inhibiting the development of plaque and gingivitis. J Clin Periodontol 1985;12:697-704.
39. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
40. Sodek J, Overall CM. Matrix metalloproteinases in periodontal tissue remodelling. Matrix Suppl 1992;1:352-362.
41. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495.
42. Leeb BF, Sautner J, Andel I, Rintelen B. Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study. Lipids 2006;41:29-34.
43. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008;233:674-688.
44. Sales C, Oliviero F, Spinella P. Role of omega-3 polyunsaturated fatty acids in diet of patients with rheumatic diseases. Reumatismo 2008;60:95-101.
45. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:797-799.
46. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004;101:15178-15183.
47. Liu D, Xu JK, Figliomeni L, et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003;11:17-21.
48. Faienza MF, Brunetti G, Colucci S, et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: The role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 2009;94:2269-2276.
49. Kawai T, Paster BJ, Komatsuzawa H, et al. Crossreactive adaptive immune response to oral commensal bacteria results in an induction of receptor activator of nuclear factor-kappaB ligand (RANKL)-dependent periodontal bone resorption in a mouse model. Oral Microbiol Immunol 2007;22:208-215.
50. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79(Suppl. 8):1569-1576.
51. Rajasekhar L, Liou LB, Chan CY, Tsai WP, Cheng CY. Matrix metalloproteinase-8 in sera and from polymorphonuclear leucocytes in rheumatoid arthritis: In vitro characterization and correlation with disease activity. Clin Exp Rheumatol 2004;22:597-602.
52. Passoja A, Ylipalosaari M, Tervonen T, Raunio T, Knuuttila M. Matrix metalloproteinase-8 concentration in shallow crevices associated with the extent of periodontal disease. J Clin Periodontol 2008;35:1027-1031.
53. Ouyang YL, Wu YF, Zhao L, Xiao XR, Zhang JY, Li XY. Matrix metalloproteinase 8 and 9 regulations of polymorphonuclear leukocytes stimulated by Porphyromonas gingivalis with different fimA genotypes [in Chinese]. Hua Xi Kou Qiang Yi Xue Za Zhi 2009;27:206-209.
54. Lamster IB, Novak MJ. Host mediators in gingival crevicular fluid: Implications for the pathogenesis of periodontal disease. Crit Rev Oral Biol Med 1992;3:31-60.
55. Bannenberg G, Arita M, Serhan CN. Endogenous receptor agonists: Resolving inflammation. Scientific-World Journal 2007;7:1440-1462.
56. González-Périz A, Horrillo R, Ferré N, et al. Obesityinduced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J 2009;23:1946-1957.
57. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 2007;282:9323-9334.
58. Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230.
59. Marchioli R, Levantesi G, Silletta MG, et al. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: Results of the GISSI-HF trial. Expert Rev Cardiovasc Ther 2009;7:735-748.
60. Paquette DW, Hanlon A, Lessem J, Williams RC. Clinical relevance of adjunctive minocycline microspheres in patients with chronic periodontitis: Secondary analysis of a phase 3 trial. J Periodontol 2004;75:531-536.
61. Garrett S, Johnson L, Drisko CH, et al. Two multicenter studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. J Periodontol 1999;70:490-503.
62. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
63. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
64. US Department of Health and Human Services: Agency for Health Care Research and Quality. Available at: www.ahrq.gov/clinic/uspstfix.htm. Accessed: November 1, 2009.